Logo image of LRMR

LARIMAR THERAPEUTICS INC (LRMR) Stock Overview

NASDAQ:LRMR - US5171251003 - Common Stock

3.62 USD
-0.29 (-7.42%)
Last: 8/29/2025, 8:00:00 PM
3.75 USD
+0.13 (+3.59%)
After Hours: 8/29/2025, 8:00:00 PM

LRMR Key Statistics, Chart & Performance

Key Statistics
52 Week High9.5
52 Week Low1.61
Market Cap309.84M
Shares85.59M
Float84.64M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.56
PEN/A
Fwd PEN/A
Earnings (Next)10-28 2025-10-28/bmo
IPO06-19 2014-06-19
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


LRMR short term performance overview.The bars show the price performance of LRMR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60

LRMR long term performance overview.The bars show the price performance of LRMR in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 -40

The current stock price of LRMR is 3.62 USD. In the past month the price increased by 5.23%. In the past year, price decreased by -54.24%.

LARIMAR THERAPEUTICS INC / LRMR Daily stock chart

LRMR Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.87 371.68B
AMGN AMGEN INC 13.19 154.89B
GILD GILEAD SCIENCES INC 14.6 140.17B
VRTX VERTEX PHARMACEUTICALS INC 23.08 100.25B
REGN REGENERON PHARMACEUTICALS 12.72 61.55B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 58.53B
ARGX ARGENX SE - ADR 76.83 43.59B
ONC BEONE MEDICINES LTD-ADR 6.16 36.38B
INSM INSMED INC N/A 28.77B
BNTX BIONTECH SE-ADR N/A 24.04B
NTRA NATERA INC N/A 23.09B
BIIB BIOGEN INC 8.26 19.38B

About LRMR

Company Profile

LRMR logo image Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company is headquartered in Bala Cynwyd, Pennsylvania and currently employs 65 full-time employees. The company went IPO on 2014-06-19. The firm is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The firm intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.

Company Info

LARIMAR THERAPEUTICS INC

Three Bala Plaza East. Suite 506

Bala Cynwyd PENNSYLVANIA 19004 US

CEO: Carole Ben-Maimon

Employees: 65

LRMR Company Website

LRMR Investor Relations

Phone: 18445119056

LARIMAR THERAPEUTICS INC / LRMR FAQ

What is the stock price of LARIMAR THERAPEUTICS INC today?

The current stock price of LRMR is 3.62 USD. The price decreased by -7.42% in the last trading session.


What is the ticker symbol for LARIMAR THERAPEUTICS INC stock?

The exchange symbol of LARIMAR THERAPEUTICS INC is LRMR and it is listed on the Nasdaq exchange.


On which exchange is LRMR stock listed?

LRMR stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for LARIMAR THERAPEUTICS INC stock?

18 analysts have analysed LRMR and the average price target is 20.03 USD. This implies a price increase of 453.29% is expected in the next year compared to the current price of 3.62. Check the LARIMAR THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is LARIMAR THERAPEUTICS INC worth?

LARIMAR THERAPEUTICS INC (LRMR) has a market capitalization of 309.84M USD. This makes LRMR a Small Cap stock.


How many employees does LARIMAR THERAPEUTICS INC have?

LARIMAR THERAPEUTICS INC (LRMR) currently has 65 employees.


What are the support and resistance levels for LARIMAR THERAPEUTICS INC (LRMR) stock?

LARIMAR THERAPEUTICS INC (LRMR) has a support level at 3.61 and a resistance level at 3.92. Check the full technical report for a detailed analysis of LRMR support and resistance levels.


Should I buy LARIMAR THERAPEUTICS INC (LRMR) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does LARIMAR THERAPEUTICS INC (LRMR) stock pay dividends?

LRMR does not pay a dividend.


When does LARIMAR THERAPEUTICS INC (LRMR) report earnings?

LARIMAR THERAPEUTICS INC (LRMR) will report earnings on 2025-10-28, before the market open.


What is the Price/Earnings (PE) ratio of LARIMAR THERAPEUTICS INC (LRMR)?

LARIMAR THERAPEUTICS INC (LRMR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.56).


What is the Short Interest ratio of LARIMAR THERAPEUTICS INC (LRMR) stock?

The outstanding short interest for LARIMAR THERAPEUTICS INC (LRMR) is 10.09% of its float. Check the ownership tab for more information on the LRMR short interest.


LRMR Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to LRMR. When comparing the yearly performance of all stocks, LRMR turns out to be only a medium performer in the overall market: it outperformed 46.46% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

LRMR Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to LRMR. No worries on liquidiy or solvency for LRMR as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

LRMR Financial Highlights

Over the last trailing twelve months LRMR reported a non-GAAP Earnings per Share(EPS) of -1.56. The EPS decreased by -39.29% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -66.53%
ROE -83.26%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-20.59%
Sales Q2Q%N/A
EPS 1Y (TTM)-39.29%
Revenue 1Y (TTM)N/A

LRMR Forecast & Estimates

18 analysts have analysed LRMR and the average price target is 20.03 USD. This implies a price increase of 453.29% is expected in the next year compared to the current price of 3.62.


Analysts
Analysts88.89
Price Target20.03 (453.31%)
EPS Next Y-33.15%
Revenue Next YearN/A

LRMR Ownership

Ownership
Inst Owners103.03%
Ins Owners1.36%
Short Float %10.09%
Short Ratio4.42